Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Amolifescience Co. Ltd. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners. The prosecution is also divided across 2 distinct art units, indicating that the company's applications are being reviewed in different specialized sections of the patent office. This structural variety suggests that the 2 pending matters may involve distinct technical aspects of the company's biotechnology research.
Joseph Paul Miano is the busiest examiner for the company, currently managing 1 pending office action. Given that there are 2 pending office actions in total, the workload is divided between the 2 distinct examiners. Practitioners should be prepared for potential differences in examination styles, as the 2 distinct art units may have varying internal guidelines. The current data shows a portfolio with a small but technically dispersed set of active patent applications, including the 1 pending office action assigned to the busiest examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MIANO, JOSEPH PAUL | 1 | 36.0% | +63.3% |
| TAKENAKA, RISA | 1 | 27.3% | +100.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17788868 | CELL CULTURE SUBSTRATE AND MANUFACTURING METHOD THEREOF | TAKENAKA, RISA | 19d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17788868 | CELL CULTURE SUBSTRATE AND MANUFACTURING METHOD THEREOF | TAKENAKA, RISA | 19d overdue |
| 18813728 | METHOD FOR MANUFACTURING YARN FOR A CELL CULTURE SCAFFOLD | MIANO, JOSEPH PAUL | — |
| Art Unit | Apps |
|---|---|
| 1631 | 1 |
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18813728 | METHOD FOR MANUFACTURING YARN FOR A CELL CULTURE SCAFFOLD | MIANO, JOSEPH PAUL | 1631 | §103Other | Final Rejection | — | Pending | Aug 23, 2024 |
| 17788868 | CELL CULTURE SUBSTRATE AND MANUFACTURING METHOD THEREOF | TAKENAKA, RISA | 1632 | §103§112 | Non-Final OA | 19d overdue | Pending | Jun 24, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial